Cisplatin or carboplatin, that is the question;Cisplatine ou carboplatine, telle est la question

Bulletin du Cancer

Volumn 98, Issue 2, 2011, Pages 164-175

  Moncharmont, Coralie ^a   Auberdiac, Pierre ^a   Mélis, Adrien ^a   Afqir, Said ^a   Pacaut, Cécile ^a   Chargari, Cyrus ^b   Merrouche, Yacine ^a   Magné, Nicolas ^a  

^a Institut de Cancerologie de la Loire   (France)

^b University of Paris Descartes   (France)

Author keywords

Bladder tumours; Carboplatin; Cisplatin; Germ cell tumours; Gynecologic tumours; Head and neck tumours; Lung cancer; Rare ovarian tumours

Indexed keywords

CARBOPLATIN; CISPLATIN;

CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; GERM CELL TUMOR; HUMAN; LUNG CANCER; QUALITY OF LIFE; REVIEW;

EID: 79953239848     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1307     Document Type: Review

References (58)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969 ; 222 : 385-6.
2. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977 ; 39 : 1357-61. (Pubitemid 8108285)
3. Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. Chemotherapy and renal toxicity. Bull Cancer 2008 ; 95 : F96-F103 (FMC Onco).
4. Durand JP, Madelaine I, Scotte F. Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 2009 ; 96 : 951-60.
5. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 ; 7 : 1748-56. (Pubitemid 19272848)
6. Egorin MJ, Echo DAV, Tippings SJ, et al. The pharmacokinetics of cis-diammine (1,1-cyclobutane dicarboxylato) platinum in patients with normal and impaired renal function. Cancer Res 1984 ; 44 : 5432-8.
7. Oudard S, Lauraine EP. Dose individualization for carboplatin in cancer chemotherapy. Bull Cancer 1997 ; 84 : 675-7. (Pubitemid 27351536)
8. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 3852-9. (Pubitemid 41079865)
9. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- vs carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007 ; 99 : 847-57.
10. Souquet PJ, Geriniere L. Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer. Bull Cancer 2002 ; 89 Spec No: S80-4.
11. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985 ; 3 : 1471-7. (Pubitemid 16246758)
12. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987 ; 5 : 1574-8. (Pubitemid 18010134)
13. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A hellenic co-operative oncology group study. Ann Oncol 1994 ; 5 : 601-7. (Pubitemid 24283096)
14. Santoro A, O'Brien M E, Stahel R A, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 2008 ; 3 : 756-63.
15. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol 1992 ; 10 : 1245-51.
16. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil vs carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995 ; 13 : 1493-500.
17. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 ; 334 : 1-6. (Pubitemid 26012496)
18. Neijt JP. New therapy for ovarian cancer. N Engl J Med 1996 ; 334 : 50-1. (Pubitemid 26012507)
19. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000 ; 18 : 3084-92.
20. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel vs carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003 ; 95 : 1320-9.
21. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003 ; 21 : 3194-200. (Pubitemid 46606249)
22. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized study of the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel vs carboplatin/paclitaxel. J Clin Oncol 2006 ; 24 : 579-86. (Pubitemid 46630419)
23. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998 ; 16 : 139-44. (Pubitemid 28041591)
24. Lhomme C, Even C, Morice P, et al. First line chemotherapy of advanced epithelial ovarian cancer. Bull Cancer 2009 ; 96 : 1207-13.
25. Jandial DD, Messer K, Farshchi-Heydari S, Pu M, Howell SB. Tumor platinum concentration following intraperitoneal administration of cisplatin vs carboplatin in an ovarian cancer model. Gynecol Oncol 2009 ; 115 : 362-6.
26. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/ paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007 ; 105 : 299-303. (Pubitemid 46590319)
27. Saito IK, Itagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I. A phase III trial of paclitaxel plus carboplatin vs paclitaxel plus cisplatin in stage IVB, persistant or recurrent cervical cancer: gynecologic cancer study group/Japan clinical oncology group study. Jpn J Clin Oncol 2010 ; 40 : 90-3.
28. vanWijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009 ; 19 : 431-46.
29. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008 ; 19 : 1847-52.
30. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010 ; 28 : 1145-53.
31. Gogas H, Pectasides D, Kostopoulos I, et al. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: a phase II trial of the hellenic cooperative oncology group. Clin Breast Cancer 2010 ; 10 : 230-7.
32. Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010 ; 116 : 4227-37.
33. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown university oncology group study. J Clin Oncol 2009 ; 27 : 4693-700.
34. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin vs etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993 ; 11 : 598-606. (Pubitemid 23105666)
35. Kattan J, Mahjoubi M, Droz JP, et al. High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer 1993 ; 29A : 1504-9. (Pubitemid 23251786)
36. Tjulandin SA, Garin AM, Mescheryakov AA, et al. Cisplatinetoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 1993 ; 4 : 663-7. (Pubitemid 23291812)
37. Horwich A, Dearnaley DP, Nicholls J, et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991 ; 9 : 62-9.
38. Bokemeyer C, Kohrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) vs carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996 ; 7 : 1015-21.
39. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional medical research council/European organization for research and treatment of cancer trial. J Clin Oncol 1997 ; 15 : 1844-52. (Pubitemid 27209513)
40. Nichols CR, Williams S, Loehrer PJ, et al. Randomized study of cisplatin dose-intensity in poor-risk germ-cell tumors: a Southeastern cancer study group and Southwest oncology group protocol. J Clin Oncol 1991 ; 9 : 1163-72.
41. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007 ; 25 : 247-56. (Pubitemid 350003012)
42. Ray-Coquard I, Pautier P, Pujade-Lauraine E, et al. Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France. Bull Cancer 2010 ; 97 : 123-35.
43. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based vs cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997 ; 80 : 1966-72. (Pubitemid 27479792)
44. Bellmunt J, Albanell J, Gallego OS, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992 ; 70 : 1974-9.
45. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 ; 23 : 4602-8. (Pubitemid 46224062)
46. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007 ; 52 : 134-41. (Pubitemid 46803003)
47. Hennequin C, Salemkour A, Mal F, et al. Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomas. Bull Cancer 2001 ; 88 : 203-7. (Pubitemid 32238732)
48. Rixe O. Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin. Bull Cancer 2000 ; 87 Spec No: 7-15.
49. Carde P, Laval F. Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 1981 ; 7 : 929-33. (Pubitemid 11017324)
50. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987 ; 13 : 403-26. (Pubitemid 17053953)
51. Omura M, Torigoe S, Kubota N. SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother Oncol 1997 ; 43 : 197-201. (Pubitemid 27261591)
52. Begg AC, van der Kolk PJ, Emondt J, Bartelink H. Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediamminemalonatoplatinum(II) (JM40). Radiother Oncol 1987 ; 9 : 157-65.
53. Dionet CA, Rapp M, Tchirkov A. Comparisons of carboplatin and cisplatin as potentiators of 5-fluorouracil and radiotherapy in the mouse L1210 leukaemia model. Anticancer Res 2002 ; 22 : 721-5. (Pubitemid 34475220)
54. Chatelut E, Canal P, Bugat R. Pharmacokinetics and individual dose adjustment of carboplatin. Bull Cancer 2000 ; 87 Spec No: 17-23.
55. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin vs carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007 ; 43 : 1399-406. (Pubitemid 46874069)
56. Barkati M, Fortin B, Soulières D, et al. Concurrent chemoradiation with carboplatin-5-fluorouracil vs cisplatin in locally advanced oropharyngeal cancers: is more always better?. Int J Radiat Oncol Biol Phys 2010 ; 76 : 410-6.
57. Eifel PJ. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat Clin Pract Oncol 2006 ; 3 : 248-55. (Pubitemid 43731110)
58. Cetina L, Garcia-Arias A, Uribe Mde J, et al. Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. Eur J Gynaecol Oncol 2008 ; 29 : 608-12.